Robert Infarinato

Phio Pharmaceuticals Corp. (PHIO)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Robert Infarinato

Phio Pharmaceuticals Corp. reported in an 8-K filed June 12, 2025 that Robert Infarinato was appointed VP, Strategic Development, effective June 9, 2025.

“Mr. Robert Infarinato has been appointed to the role of VP, Strategic Development, effective June 9, 2025.”

Phio Pharmaceuticals Corp. Form 8-K, filed June 12, 2025 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Research with Equibles

Turn this profile into a cited research brief

Start with a question tailored to the filings and events on this page, or connect Equibles financial data to ChatGPT or Claude.

Suggested question: “Summarize Robert Infarinato's recent executive appointments or departures and cite the source filings.”

Use in your AI

Affiliation history

Recorded current and former roles; source labels appear when available.

Phio Pharmaceuticals Corp. (PHIO)
SEC 8-K

Current
2025-06-09–present

Company network

Recorded roles and call appearances connecting this person to public companies.

Phio Pharmaceuticals Corp.

PHIO

Current role

Leadership on record at Phio Pharmaceuticals Corp.

Other people whose current roles at this company are on record from its filings.

Geert Cauwenbergh CEO
Geert Cauwenbergh, Dr. Med. Sc. CEO
Gerrit Dispersyn CEO, Board Member
Robert Bitterman CEO
Robert J. Bitterman CEO, Chairman, Board Member
Lisa Carson CFO
Robert M. Infarinato CFO, Chief Accounting Officer
Curtis A. Lockshin, Ph.D. Board Member
David H. Deming Board Member
Jonathan E. Freeman, Ph.D. Board Member

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Executive change Appointed: VP, Strategic Development Phio Pharmaceuticals Corp. (PHIO)
2025-06-09